When it is more
than a cough

DO YOU RECOGNIZE THESE PATIENTS?TREAT OR REFER IMMEDIATELY! FACE IPF HEAD ON!

There is no cure, but antifibrotic treatments could slow IPF progression1

Suspect IPF when you first see a combination of its clues2

Finger
Clubbing

Dyspnoea
Cough

ipf?

References: 1. Fujimoto H, Kobayashi T, Azuma A. Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med. 2016;9(Suppl 1):179–185. 2. National Clinical Guideline Centre (UK). Diagnosis and management of suspected idiopathic pulmonary fibrosis: idiopathic pulmonary fibrosis. London: Royal College of Physicians (UK) 2013.Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med. 2014;108(6):819–829.

  • To report any Adverse events please use PV_local_South_Africa@boehringer-ingelheim.com
  • Should you require any further clinical information about OFEV®, please do not hesitate to contact me at renard.prinsloo@boehringer-ingelheim.com
  • S4 OFEV® 100 mg contains 100 mg nintedanib base (as esilate salt) Reg. No./Nr.: A 52/26/0153.
  • S4 OFEV® 150 mg contains 150 mg nintedanib base (as esilate salt) Reg. No./Nr.: A 52/26/0154.
  • For full prescribing information refer to the professional information approved by the Regulatory Authority.
  • Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd. Suite 1, Building 4, 2nd Floor, Waterfall Corporate Campus, 74 Waterfall Drive, Midrand, 2066,
    South Africa. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008619/07. BI Ref. No. PC-ZA-101638. Expiry date: March 2024.